250 related articles for article (PubMed ID: 32656891)
1. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Zhou Y; Ye Z; Lu J; Miao S; Lu X; Sun H; Wu J; Wang Y; Huang Y
Helicobacter; 2020 Oct; 25(5):e12721. PubMed ID: 32656891
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Wang HM; Tsai TJ; Wu DC; Chen CL; Tsai KW;
Helicobacter; 2018 Aug; 23(4):e12498. PubMed ID: 29897654
[TBL] [Abstract][Full Text] [Related]
3. Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
Zhou Y; Ye Z; Wang Y; Huang Z; Zheng C; Shi J; Tang W; Zhang P; Wang S; Huang Y
Helicobacter; 2021 Aug; 26(4):e12809. PubMed ID: 33899288
[TBL] [Abstract][Full Text] [Related]
4. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
[TBL] [Abstract][Full Text] [Related]
6. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults.
He C; Peng C; Wang H; Ouyang Y; Zhu Z; Shu X; Zhu Y; Lu N
Helicobacter; 2019 Aug; 24(4):e12590. PubMed ID: 31124220
[TBL] [Abstract][Full Text] [Related]
7. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Liou JM; Chen CC; Chang CM; Fang YJ; Bair MJ; Chen PY; Chang CY; Hsu YC; Chen MJ; Chen CC; Lee JY; Yang TH; Luo JC; Chen CY; Hsu WF; Chen YN; Wu JY; Lin JT; Lu TP; Chuang EY; El-Omar EM; Wu MS;
Lancet Infect Dis; 2019 Oct; 19(10):1109-1120. PubMed ID: 31559966
[TBL] [Abstract][Full Text] [Related]
8. Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
Chen J; Zhang Y; Min H; Zhi J; Ma S; Dong H; Yan J; Chi X; Zhang X; Yang Y
Helicobacter; 2024; 29(2):e13077. PubMed ID: 38682268
[TBL] [Abstract][Full Text] [Related]
9. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.
Xie Y; Pan X; Li Y; Wang H; Du Y; Xu J; Wang J; Zeng Z; Chen Y; Zhang G; Wu K; Liu D; Lv N
J Antimicrob Chemother; 2018 Jun; 73(6):1681-1687. PubMed ID: 29596646
[TBL] [Abstract][Full Text] [Related]
10. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
[TBL] [Abstract][Full Text] [Related]
11. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota.
Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Chen YH; Tsai TJ; Wu DC; Tsai KW
J Gastroenterol Hepatol; 2019 Nov; 34(11):1968-1976. PubMed ID: 31115933
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
[TBL] [Abstract][Full Text] [Related]
13. Metagenomic Changes of Gut Microbiota following Treatment of
Dore MP; Sau R; Niolu C; Abbondio M; Tanca A; Bibbò S; Loria M; Pes GM; Uzzau S
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889746
[TBL] [Abstract][Full Text] [Related]
14. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
[TBL] [Abstract][Full Text] [Related]
15. One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer.
Sung JJ; Leung WK; Ling TK; Yung MY; Chan FK; Lee YT; Cheng AF; Chung SC
Aliment Pharmacol Ther; 1998 Aug; 12(8):725-30. PubMed ID: 9726384
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Labenz J; Stolte M; Peitz U; Tillenburg B; Köhl H; Becker T; Börsch G
Z Gastroenterol; 1995 Oct; 33(10):590-3. PubMed ID: 7502551
[TBL] [Abstract][Full Text] [Related]
17. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
Tarhini M; Fayyad-Kazan M; Fayyad-Kazan H; Mokbel M; Nasreddine M; Badran B; Kchour G
Microb Pathog; 2018 Apr; 117():23-26. PubMed ID: 29428426
[TBL] [Abstract][Full Text] [Related]
19. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial.
Kaviani MJ; Malekzadeh R; Vahedi H; Sotoudeh M; Kamalian N; Amini M; Massarrat S
Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):915-9. PubMed ID: 11507355
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.
Luo L; Huang Y; Liang X; Ji Y; Yu L; Lu H
Helicobacter; 2020 Aug; 25(4):e12699. PubMed ID: 32428369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
